8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 9, 2026·SEC
Zevra Therapeutics, Inc.(ZVRA)Earnings, Financials & Key Ratios
ZVRA•NASDAQ
9.6× P/E·Price updated Jun 19, 2026
AboutZevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.Show more
- Revenue$106M+350.9%
- EBITDA-$179K+99.8%
- Net Income$83M+178.9%
- EPS (Diluted)1.35+159.2%
- Gross Margin84.52%+23.2%
- EBITDA Margin-0.17%+100.0%
- Operating Margin-3.98%+98.9%
- Net Margin78.17%+117.5%
- ROE85.66%+141.2%
ZVRA Key Insights
Zevra Therapeutics, Inc. (ZVRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓Strong 5Y sales CAGR of 51.6%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 23.8% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ZVRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZVRA Price & Volume
Zevra Therapeutics, Inc. (ZVRA) stock price & volume — 10-year historical chart
Loading chart...
ZVRA Growth Metrics
Zevra Therapeutics, Inc. (ZVRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years51.62%
3 Years118.82%
TTM201.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM235.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM213.33%
Return on Capital
10 Years-79.79%
5 Years-29.6%
3 Years-41%
Last Year-2.17%
ZVRA Recent Earnings
Zevra Therapeutics, Inc. (ZVRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.18+200.0%
$0.06
Rev
$36M+13.3%
$32M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$1.16+2201.6%
$0.05
Rev
$34M+21.6%
$28M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.01+50.0%
$0.02
Rev
$26M-2.2%
$27M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$1.21-44.7%
$2.19
Rev
$26M+5.6%
$25M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.18vs $0.06+200.0% | $36Mvs $32M+13.3% |
| Q2 2026 | Mar 9, 2026 | $1.16vs $0.05+2201.6% | $34Mvs $28M+21.6% |
| Q4 2025 | Nov 5, 2025 | $0.01vs $0.02+50.0% | $26Mvs $27M-2.2% |
| Q3 2025 | Aug 12, 2025 | $1.21vs $2.19-44.7% | $26Mvs $25M+5.6% |
Based on last 12 quarters of dataView full earnings history →
ZVRA Peer Comparison
Zevra Therapeutics, Inc. (ZVRA) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 ACHC | 2.29B | 24.87 | -2.05 | 5.04% | -32.84% | -40.92% | 1.24 | |
 ACRS | 542.68M | 4.50 | -8.49 | -58.19% | -8.33% | -55.89% | 0.02 | |
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 |
Compare ZVRA vs Peers
Zevra Therapeutics, Inc. (ZVRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZVRA Income Statement
Zevra Therapeutics, Inc. (ZVRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 12.84M | 13.29M | 28.65M | 10.16M | 27.46M | 23.61M | 106.47M | 122.29M |
Revenue Growth % | - | - | - | 3.5% | 115.61% | -64.53% | 170.26% | -14.02% | 350.91% | 201.29% |
Cost of Goods Sold | 336K | 324K | 2.94M | 1.3M | 2.06M | 222K | 2.94M | 7.42M | 16.48M | 17.35M |
COGS % of Revenue | - | - | 22.94% | 9.82% | 7.19% | 2.18% | 10.72% | 31.41% | 15.48% | - |
Gross Profit | -336K▲ 0% | -324K▲ 3.6% | 9.89M▲ 3153.7% | 11.98M▲ 21.1% | 26.59M▲ 121.9% | 9.94M▼ 62.6% | 24.52M▲ 146.7% | 16.2M▼ 33.9% | 89.99M▲ 455.7% | 104.94M▲ 0% |
Gross Margin % | - | - | 77.06% | 90.18% | 92.81% | 97.82% | 89.28% | 68.59% | 84.52% | 85.81% |
Gross Profit Growth % | -92% | 3.57% | 3153.7% | 21.11% | 121.91% | -62.62% | 146.66% | -33.94% | 455.65% | - |
Operating Expenses | 33.37M | 54.27M | 30.23M | 17.59M | 18.86M | 52.5M | 74.12M | 103.2M | 94.22M | 153.37M |
OpEx % of Revenue | - | - | 235.46% | 132.39% | 65.84% | 516.72% | 269.91% | 437.06% | 88.5% | - |
Selling, General & Admin | 12.77M | 12.51M | 10.82M | 7.92M | 8.7M | 15.04M | 35.09M | 54.87M | 77.62M | 78.85M |
SG&A % of Revenue | - | - | 84.24% | 59.61% | 30.37% | 148% | 127.78% | 232.37% | 72.9% | - |
Research & Development | 20.59M | 41.76M | 19.41M | 8.84M | 10.16M | 19.8M | 39.81M | 42.09M | 12.74M | 13.88M |
R&D % of Revenue | - | - | 151.22% | 66.55% | 35.47% | 194.89% | 144.95% | 178.28% | 11.97% | - |
Other Operating Expenses | 0 | 0 | 0 | 828K | 0 | 17.66M | -775K | 6.24M | 3.86M | 1.32M |
Operating Income | -33.37M▲ 0% | -55.9M▼ 67.5% | -20.34M▲ 63.6% | -5.61M▲ 72.4% | 7.73M▲ 237.8% | -42.56M▼ 650.7% | -49.6M▼ 16.5% | -87M▼ 75.4% | -4.23M▲ 95.1% | -5.43M▲ 0% |
Operating Margin % | - | - | -158.4% | -42.21% | 26.98% | -418.91% | -180.63% | -368.47% | -3.98% | -4.44% |
Operating Income Growth % | 10.98% | -67.54% | 63.62% | 72.42% | 237.8% | -650.72% | -16.54% | -75.4% | 95.13% | - |
EBITDA | -33.03M | -55.58M | -20.03M | -5.34M | 7.99M | -41.62M | -48.6M | -80.61M | -179K | -3.03M |
EBITDA Margin % | - | - | -156.03% | -40.16% | 27.87% | -409.62% | -176.97% | -341.41% | -0.17% | -2.48% |
EBITDA Growth % | 11.46% | -68.27% | 63.96% | 73.36% | 249.66% | -621.17% | -16.76% | -65.88% | 99.78% | 95.37% |
D&A (Non-Cash Add-back) | 336K | 324K | 304K | 273K | 257K | 944K | 1.01M | 6.39M | 4.05M | 2.4M |
EBIT | -33.37M | -54.27M | -18.03M | -5.7M | -8.14M | -26.47M | -44.55M | -82.79M | 94.66M | 94.6M |
Net Interest Income | -6.97M | -6.67M | -6.21M | -7M | -115K | 1.18M | 3.04M | -5.18M | -1.03M | -2.58M |
Interest Income | 365K | 420K | 309K | 89K | 261K | 1.51M | 4.54M | 2.17M | 6.95M | 1.71M |
Interest Expense | 7.34M | 7.09M | 6.51M | 7.09M | 376K | 335K | 1.5M | 7.35M | 7.98M | 4.3M |
Other Income/Expense | -10.06M | -689K | -4.21M | -7.18M | -16.25M | 15.76M | 3.56M | -3.14M | 90.91M | 138.83M |
Pretax Income | -43.43M▲ 0% | -56.59M▼ 30.3% | -24.54M▲ 56.6% | -12.79M▲ 47.9% | -8.52M▲ 33.4% | -26.8M▼ 214.6% | -46.05M▼ 71.8% | -90.14M▼ 95.7% | 86.68M▲ 196.2% | 133.4M▲ 0% |
Pretax Margin % | - | - | -191.17% | -96.28% | -29.74% | -263.8% | -167.69% | -381.75% | 81.41% | 109.09% |
Income Tax | -43K | -126K | -22K | -34K | 34K | -33K | 0 | 15.37M | 3.45M | -4.65M |
Effective Tax Rate % | 0.1% | 0.22% | 0.09% | 0.27% | -0.4% | 0.12% | 0% | -17.05% | 3.98% | -3.48% |
Net Income | -43.39M▲ 0% | -56.47M▼ 30.1% | -24.52M▲ 56.6% | -12.76M▲ 48.0% | -8.55M▲ 33.0% | -26.77M▼ 212.9% | -46.05M▼ 72.0% | -105.51M▼ 129.1% | 83.23M▲ 178.9% | 124.22M▲ 0% |
Net Margin % | - | - | -191% | -96.03% | -29.86% | -263.48% | -167.69% | -446.85% | 78.17% | 101.58% |
Net Income Growth % | -162.69% | -30.15% | 56.57% | 47.97% | 32.95% | -212.94% | -72% | -129.13% | 178.88% | 235.04% |
Net Income (Continuing) | -43.39M | -56.47M | -24.52M | -12.76M | -8.55M | -26.77M | -46.05M | -105.51M | 83.23M | 124.22M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -47.37▲ 0% | -50.39▼ 6.4% | -13.23▲ 73.7% | -3.21▲ 75.7% | -2.11▲ 34.3% | -0.78▲ 63.0% | -1.30▼ 66.7% | -2.28▼ 75.4% | 1.35▲ 159.2% | 2.06▲ 0% |
EPS Growth % | -161.71% | -6.38% | 73.74% | 75.74% | 34.27% | 63.03% | -66.67% | -75.38% | 159.21% | 213.33% |
EPS (Basic) | -47.37 | -50.39 | -13.23 | -3.21 | -2.11 | -0.78 | -1.30 | -2.28 | 1.40 | - |
Diluted Shares Outstanding | 915.81K | 1.12M | 1.85M | 3.98M | 29.77M | 34.49M | 35.45M | 46.25M | 57.26M | 60.23M |
Basic Shares Outstanding | 915.81K | 1.12M | 1.85M | 3.98M | 29.77M | 34.49M | 35.45M | 46.25M | 55.31M | 58.41M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ZVRA Balance Sheet
Zevra Therapeutics, Inc. (ZVRA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 45.9M | 23.72M | 6.97M | 8.38M | 115.06M | 92.83M | 86.94M | 86.03M | 223.01M | 229.97M |
Cash & Short-Term Investments | 42.23M | 21.67M | 3.22M | 4.21M | 112.35M | 82.85M | 67.74M | 69.5M | 191.01M | 95.59M |
Cash Only | 10.87M | 18.41M | 3.22M | 4.21M | 112.35M | 65.47M | 43.05M | 33.78M | 62.41M | 95.59M |
Short-Term Investments | 31.36M | 3.26M | 0 | 0 | 0 | 17.38M | 24.69M | 35.71M | 128.6M | 0 |
Accounts Receivable | 2.08M | 140K | 1.86M | 2.58M | 1.53M | 8.3M | 17.38M | 10.51M | 23.26M | 22.1M |
Days Sales Outstanding | - | - | 53.02 | 70.84 | 19.47 | 298.11 | 230.97 | 162.45 | 79.73 | 60.04 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 24.08M | 1.97M | 1.74M | 2.31M |
Days Inventory Outstanding | - | - | - | - | - | - | 2.98K | 96.95 | 38.53 | 34.32 |
Other Current Assets | 1.38M | 0 | 1.37M | 312K | 252K | 1.11M | -23.43M | 3.02M | 7M | 109.97M |
Total Non-Current Assets | 6.56M | 3.02M | 3.54M | 2.83M | 17.89M | 22.51M | 85.39M | 92.1M | 61.72M | 48.61M |
Property, Plant & Equipment | 2M | 1.75M | 3.01M | 2.39M | 2.02M | 1.78M | 1.53M | 1.01M | 1.7M | 1.52M |
Fixed Asset Turnover | - | - | 4.27x | 5.56x | 14.15x | 5.70x | 18.00x | 23.31x | 62.59x | 68.53x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 4.7M | 4.7M | 4.7M | 4.7M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 69.23M | 68.99M | 6.42M | 6.11M |
Long-Term Investments | 3.25M | 0 | 0 | 0 | 15.42M | 20M | 0 | 6.01M | 47.88M | 129.98M |
Other Non-Current Assets | 1.31M | 1.27M | 527K | 438K | 438K | 724K | 9.94M | 11.38M | 1.02M | 143K |
Total Assets | 52.46M▲ 0% | 26.75M▼ 49.0% | 10.51M▼ 60.7% | 11.21M▲ 6.7% | 132.94M▲ 1086.0% | 115.34M▼ 13.2% | 172.33M▲ 49.4% | 178.13M▲ 3.4% | 284.73M▲ 59.8% | 278.58M▲ 0% |
Asset Turnover | - | - | 1.22x | 1.19x | 0.22x | 0.09x | 0.16x | 0.13x | 0.37x | 0.45x |
Asset Growth % | -38.2% | -49.01% | -60.72% | 6.68% | 1086.02% | -13.24% | 49.41% | 3.37% | 59.85% | 239.63% |
Total Current Liabilities | 11.51M | 12M | 5.43M | 7.54M | 4.23M | 12.02M | 73.72M | 34.06M | 39.28M | 47.03M |
Accounts Payable | 2.18M | 3.71M | 1.14M | 1.17M | 516K | 3.61M | 13.99M | 13.07M | 2.48M | 0 |
Days Payables Outstanding | 2.36K | 4.19K | 141.29 | 328.36 | 91.47 | 5.94K | 1.73K | 643.44 | 54.88 | 71.27 |
Short-Term Debt | 3.33M | 3.33M | 0 | 390K | 0 | 4.66M | 37.7M | 0 | 0 | 406K |
Deferred Revenue (Current) | 5.7M | 4.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -5.59M | -4.51M | 236K | 0 | 821K | 719K | 10.82M | 3.2M | 22.67M | 46.62M |
Current Ratio | 3.99x | 1.98x | 1.28x | 1.11x | 27.20x | 7.72x | 1.18x | 2.53x | 5.68x | 4.89x |
Quick Ratio | 3.99x | 1.98x | 1.28x | 1.11x | 27.20x | 7.72x | 0.85x | 2.47x | 5.63x | 4.84x |
Cash Conversion Cycle | - | - | - | - | - | - | 1.48K | -384.04 | 63.39 | 23.09 |
Total Non-Current Liabilities | 98.46M | 81.31M | 79.53M | 70.08M | 1.59M | 28.2M | 36.74M | 104.4M | 90.8M | 25.75M |
Long-Term Debt | 89.4M | 78.11M | 77.34M | 68.05M | 0 | 12.8M | 5.07M | 59.5M | 61.93M | 741K |
Capital Lease Obligations | 562K | 396K | 1.9M | 1.61M | 1.24M | 843K | 456K | 372K | 859K | 2.88M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8.5M | 2.81M | 288K | 427K | 355K | 14.55M | 31.22M | 44.52M | 28.01M | 25.01M |
Total Liabilities | 109.97M | 93.31M | 84.96M | 77.62M | 5.82M | 40.22M | 110.46M | 138.46M | 130.07M | 72.78M |
Total Debt | 93.48M | 82.05M | 79.53M | 70.55M | 1.61M | 18.78M | 43.77M | 60.3M | 63.21M | 1.15M |
Net Debt | 82.61M | 63.64M | 76.31M | 66.33M | -110.74M | -46.69M | 716K | 26.51M | 800K | -94.45M |
Debt / Equity | - | - | - | - | 0.01x | 0.25x | 0.71x | 1.52x | 0.41x | 0.01x |
Debt / EBITDA | - | - | - | - | 0.20x | - | - | - | - | -0.38x |
Net Debt / EBITDA | - | - | - | - | -13.87x | - | - | - | - | 31.17x |
Interest Coverage | -4.55x | -7.66x | -2.77x | -0.80x | -21.66x | -79.01x | -29.68x | -11.26x | 11.87x | 22.02x |
Total Equity | -57.52M▲ 0% | -66.57M▼ 15.7% | -74.46M▼ 11.9% | -66.41M▲ 10.8% | 127.12M▲ 291.4% | 75.12M▼ 40.9% | 61.86M▼ 17.6% | 39.67M▼ 35.9% | 154.66M▲ 289.9% | 205.8M▲ 0% |
Equity Growth % | -207.64% | -15.73% | -11.85% | 10.8% | 291.41% | -40.91% | -17.65% | -35.88% | 289.9% | 1043.39% |
Book Value per Share | -62.80 | -59.40 | -40.17 | -16.68 | 4.27 | 2.18 | 1.74 | 0.86 | 2.70 | 3.42 |
Total Shareholders' Equity | -57.52M | -66.57M | -74.46M | -66.41M | 127.12M | 75.12M | 61.86M | 39.67M | 154.66M | 205.8M |
Common Stock | 1K | 3K | 0 | 0 | 4K | 3K | 4K | 5K | 6K | 6K |
Retained Earnings | -164.73M | -221.19M | -245.71M | -258.47M | -267.03M | -353.73M | -399.78M | -505.29M | -422.06M | -384.17M |
Treasury Stock | 0 | 0 | 0 | 0 | -2.81M | -7.54M | -10.98M | -10.98M | -10.98M | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 113K | -43K | 631K | -764K | -1.8M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZVRA Cash Flow Statement
Zevra Therapeutics, Inc. (ZVRA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -33.1M | -54.2M | -23.74M | -1.94M | 10.44M | -18.72M | -33.53M | -69.67M | -1.6M | 12.77M |
Operating CF Margin % | - | - | -184.88% | -14.59% | 36.44% | -184.2% | -122.12% | -295.04% | -1.5% | - |
Operating CF Growth % | -11.18% | -63.76% | 56.21% | 91.83% | 638.37% | -279.3% | -79.17% | -107.74% | 97.71% | 515.76% |
Net Income | -43.39M | -56.47M | -24.52M | -12.76M | -8.55M | -41.54M | -46.05M | -105.51M | 83.23M | 124.22M |
Depreciation & Amortization | 336K | 324K | 304K | 273K | 257K | 944K | 1.01M | 6.39M | 4.05M | 2.77M |
Stock-Based Compensation | 4.56M | 6.5M | 4.41M | 2.49M | 2.44M | 4.29M | 5.95M | 14.91M | 12.63M | 9.52M |
Deferred Taxes | 164K | -5.98M | -2M | 435K | 16.2M | 0 | 0 | 15.37M | 3.45M | 2.27M |
Other Non-Cash Items | 6.87M | 3.71M | 3.19M | 7.25M | 460K | 17.99M | -329K | 5.82M | -78.45M | -114.36M |
Working Capital Changes | -1.65M | -2.29M | -5.12M | 374K | -357K | -406K | 5.88M | -6.64M | -26.51M | -10.08M |
Change in Receivables | 0 | 0 | -1.73M | -714K | 1.05M | -6.77M | -9.08M | 6.87M | -11.98M | -2.98M |
Change in Inventory | 0 | 0 | 5.51M | 0 | 0 | 147K | 206K | -8.87M | -1.3M | -1.28M |
Change in Payables | -801K | -1.64M | -3.79M | 931K | -1.11M | 3.13M | 11.13M | -3.6M | -15.59M | -8.85M |
Cash from Investing | 27.41M | 33.33M | 3.23M | -33K | -15.52M | -36.72M | -17.39M | -22.16M | 18.13M | 87.2M |
Capital Expenditures | -181K | -21K | -26K | -33K | -102K | -93K | -296K | 0 | -835K | -771K |
CapEx % of Revenue | - | - | 0.2% | 0.25% | 0.36% | 0.92% | 1.08% | - | 0.78% | 0.63% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -14.09M | -30.4M | 0 | 0 | 42K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 27.59M | 33.35M | 0 | 0 | 0 | -36.63M | 0 | -6M | 448K | 44.38M |
Cash from Financing | -203K | 28.02M | 4.94M | 2.74M | 113.11M | 8.35M | 28.46M | 82.11M | 12.06M | -42.35M |
Debt Issued (Net) | -157K | -193K | 5.24M | 2.86M | -38.1M | 12.78M | 25.59M | 16.29M | 0 | -60.09M |
Equity Issued (Net) | 0 | 28.33M | 0 | -84K | 46.47M | -4.72M | -3.45M | 64.52M | 12.44M | 20.38M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -2.81M | -4.72M | -3.45M | 0 | 0 | 0 |
Other Financing | -46K | -116K | -300K | -34K | 104.73M | 291K | 6.32M | 1.3M | -372K | -2.63M |
Net Change in Cash | -5.89M▲ 0% | 7.15M▲ 221.3% | -15.56M▼ 317.7% | 767K▲ 104.9% | 108.02M▲ 13984.0% | -46.88M▼ 143.4% | -22.42M▲ 52.2% | -9.26M▲ 58.7% | 28.62M▲ 408.9% | 58.26M▲ 0% |
Free Cash Flow | -33.28M▲ 0% | -54.22M▼ 62.9% | -23.76M▲ 56.2% | -1.97M▲ 91.7% | 10.34M▲ 624.2% | -18.81M▼ 282.0% | -33.83M▼ 79.9% | -69.67M▼ 105.9% | -2.43M▲ 96.5% | 11.99M▲ 0% |
FCF Margin % | - | - | -185.08% | -14.84% | 36.08% | -185.12% | -123.2% | -295.04% | -2.29% | 9.81% |
FCF Growth % | -9.42% | -62.93% | 56.18% | 91.7% | 624.19% | -281.97% | -79.86% | -105.92% | 96.51% | 119.4% |
FCF per Share | -36.34 | -48.39 | -12.82 | -0.50 | 0.35 | -0.55 | -0.95 | -1.51 | -0.04 | 0.20 |
FCF Conversion (FCF/Net Income) | 0.76x | 0.96x | 0.97x | 0.15x | -1.22x | 0.70x | 0.73x | 0.66x | -0.02x | 0.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.37M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZVRA Key Ratios
Zevra Therapeutics, Inc. (ZVRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | - | -28.18% | -26.48% | -67.23% | -207.84% | 85.66% | 81.34% |
Return on Invested Capital (ROIC) | -61.32% | -378.27% | -822.25% | -473.47% | 71.11% | -142.48% | -81.75% | -101.36% | -2.86% | -3.02% |
Gross Margin | - | - | 77.06% | 90.18% | 92.81% | 97.82% | 89.28% | 68.59% | 84.52% | 85.81% |
Net Margin | - | - | -191% | -96.03% | -29.86% | -263.48% | -167.69% | -446.85% | 78.17% | 101.58% |
Debt / Equity | - | - | - | - | 0.01x | 0.25x | 0.71x | 1.52x | 0.41x | 0.01x |
Interest Coverage | -4.55x | -7.66x | -2.77x | -0.80x | -21.66x | -79.01x | -29.68x | -11.26x | 11.87x | 22.02x |
FCF Conversion | 0.76x | 0.96x | 0.97x | 0.15x | -1.22x | 0.70x | 0.73x | 0.66x | -0.02x | 0.10x |
Revenue Growth | - | - | - | 3.5% | 115.61% | -64.53% | 170.26% | -14.02% | 350.91% | 201.29% |
Related:ZVRA Dividend History·ZVRA Revenue History·ZVRA Price History·ZVRA P/E History·ZVRA Financial Ratios·ZVRA Institutional Holders
ZVRA SEC Filings & Documents
Zevra Therapeutics, Inc. (ZVRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZVRA Frequently Asked Questions
Zevra Therapeutics, Inc. (ZVRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zevra Therapeutics, Inc. (ZVRA) reported $122.3M in revenue for fiscal year 2025.
Zevra Therapeutics, Inc. (ZVRA) grew revenue by 350.9% over the past year. This is strong growth.
Yes, Zevra Therapeutics, Inc. (ZVRA) is profitable, generating $124.2M in net income for fiscal year 2025 (78.2% net margin).
Dividend & Returns
Zevra Therapeutics, Inc. (ZVRA) has a return on equity (ROE) of 85.7%. This is excellent, indicating efficient use of shareholder capital.
Zevra Therapeutics, Inc. (ZVRA) generated $12.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.